Open Access

Vitamin D role in smoking women and cardiac remodeling

  • Melaine Priscila Fidelix1Email author,
  • Suzana Erico Tanni1,
  • Meliza Goi Roscani1,
  • Carolina Bonfanti Mesquita1,
  • Karime Nafad de Melo Schelini1,
  • Bertha Furlan Polegato1,
  • Paula Schmidt Azevedo Gaiolla1,
  • Marcos Ferreira Minicucci1,
  • Leonardo Antonio Memede Zornoff1,
  • Silvia Justina Papini2,
  • Irma de Godoy1 and
  • Sergio Alberto Rupp de Paiva1
Nutrire201641:13

DOI: 10.1186/s41110-016-0012-z

Received: 7 January 2016

Accepted: 6 July 2016

Published: 24 August 2016

Abstract

Background

The objective of the study is to evaluate the influence of serum vitamin D concentrations and smoking status in cardiac structure and function.

Methods

The participants of this study were healthy women smokers (n = 18, mean age 52.8 years), ex-smokers (n = 18, mean age 51.7 years), and never smokers (n = 19, mean age 44.4 years). All participants underwent assessment of body composition, dietary intake, sun exposure frequency, vitamin D serum determination, and echocardiographic assessment. All data underwent statistical analysis.

Results

The three groups were classified as overweight. The group of ex-smokers showed significantly higher vitamin D serum concentrations. Smoker group showed a higher posterior wall thickness (PW), left ventricular mass, and left ventricular mass index (LVMI). We identified positive correlations between LVMI and smoking history, PW and vitamin D serum, and body mass index and time of smoking history. Multiple linear regressions showed positive association of smoking history and LVMI and PW, also that serum vitamin D has a positive association with PW. PW was associated with smoking history and serum vitamin D, showing a deleterious effect on the heart of both variables.

Conclusions

Smoking habit in adult women was associated with cardiac remodeling, and excess of vitamin D is associated with the action of smoking on cardiac variables. Thus, higher serum vitamin D values have a deleterious effect on the heart in this model.

Keyword

Smoking Nutrition Myocardial dysfunction Vitamin D

Background

More than one billion individuals worldwide are estimated to have vitamin D deficiency [1]. Additionally, the list of disorders associated with vitamin D deficiency continues to grow [2]. In addition to its classical functions, vitamin D deficiency is associated with cancer, neurodegenerative diseases, cardiovascular diseases, and mortality of all causes [36]. Vitamin D deficiency is described as a potential risk factor for cardiovascular disease, primarily ventricular hypertrophy and congestive heart failure [3, 7, 8]. Recently, an experimental study showed that vitamin D-deficient-diet-fed rats presented with cardiac hypertrophy as well as reduced left ventricular fractional shortening and ejection fraction [9]. Furthermore, Mancuso et al. [10] showed an attenuation of cardiac hypertrophy when rats with heart failure received chow with vitamin D supplementation.

Together with deficiency/excess vitamin D, smoking is a risk factor for cardiovascular disease and is the primary cause of preventable death worldwide [11]. Cigarette smoke is thrombogenic, atherogenic, and promotes direct aggression to the heart [12]. Experimental studies showed that animals exposed to cigarette smoke have cardiac alterations also known as cardiac remodeling [1316]. Clinical studies also showed the effects of cigarette smoking on ventricular remodeling and heart function [17, 18].

Several authors studied the association between vitamin D and tobacco smoke exposure. Hill et al. [19] observed in a clinical study that smoking was negatively associated with serum vitamin D concentrations in Irish women and in Australia, smokers had lower levels of serum vitamin D [20]. Moreover, Rafacho et al. [16] supplemented cigarette-smoke-exposed rats with vitamin D and observed an attenuation of cardiac remodeling. This study suggests that vitamin D status could influence cardiac alterations caused by tobacco smoke. Thus, the hypothesis of this study is that vitamin D deficiency could worsen cardiac alterations induced by cigarette smoke.

Objective

The objective of the study is to evaluate the influence of serum vitamin D concentrations and smoking status in cardiac structure and function.

Methods

The study was approved by the ethics committee, and the written informed consent was obtained from all of the participants. The sample size was calculated based on the average serum vitamin D concentration, an expectation of a 3 ng/mL difference and a residual expected standard deviation of 2.8 ng/mL for comparing the three groups. Assumptions made were 80 % power and a significance value of <0.05. Using these values, we obtained 18 subjects per group.

A total of 18 active female smokers and 18 female ex-smokers, who were participating in a smoking cessation group, were evaluated. All of the participants, whether smokers or ex-smokers, presented with a history of smoking greater than ten pack-years. Ex-smokers were defined as those who had stopped smoking for more than 6 months before enrollment. Only women were evaluated because of their higher prevalence in our smoking cessation program and to obtain greater homogeneity between groups. The control group consisted of 19 healthy women that were never smokers. Exclusion criteria were as follows: presence of severe or chronic diseases such as hypertension, diabetes, and respiratory diseases; supplementation of calcium and vitamin D; age below 30 years old; body mass index (BMI) higher than 30 kg/m2; and menopause.

Body composition assessment

Participant weight and height were measured, and BMI was calculated (kg/m2). BMI was classified according to the cutoff suggested by the WHO [21]. The fat-free mass index (FFMI) and fat mass index (FMI) were estimated (FFM/height2 and FMI/height2) based on dual-energy X-ray absorptiometry exam (DXA) using the Hologic instrument, model Discovery A, Bedford, MA, USA. Automated quantification of regional body tissue weights was performed with APEX System software version 2.3.1.

Dietary intake assessment

To assess dietary vitamin D intake, a 24-h recall was used in triplicates. Data from the three food records were calculated using the Nutrition Data System for Research-Grad Pack Software, which was developed by the Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN.

Sun exposure assessment

A sun exposure frequency questionnaire was used to analyze the sun exposure of participant. Each answer contained a value defined as an index of sun exposure ranging from 0 (no sun exposure) to 38 (high sun exposure) [22].

Biochemical assessment

Peripheral venous blood was obtained after a 12-h fast in the early morning (8:00 to 10:00 a.m.) to collect 25(OH) vitamin D3, calcium, and parathyroid hormone (PTH) levels. 25(OH) vitamin D3 levels were measured by chemiluminescence (Abbott®). Vitamin D deficiency was defined as serum vitamin D levels lower than 12 ng/mL. Risk for inadequacy was defined as serum levels of 25(OH) vitamin D3 from 12 to 20 ng/mL, and sufficient levels were above 20 ng/mL [23].

Echocardiographic assessment

Transthoracic echocardiography was performed to evaluate cardiac morphology and function by the same operator. The echocardiograph was a General Electric (GE) equipment Vivid 6S with phased-array multifrequency transducers of 2.5 to 3.5 MHz and an image registration system. Images were obtained and analyzed following the recommendations of the American Society of Echocardiography [24]. Intraobserver variability was lower than 3 %. Left ventricular systolic function was evaluated by measuring the ejection fraction according to the Simpson method.

Statistical analysis

ANOVA test was used to compare means between the three groups when the distribution was normal, followed by Tukey’s test for pairwise comparisons. The Kruskal-Wallis test followed by Dunn’s test was used to compare variables with nonparametric distribution. Pearson’s or Spearman’s correlation coefficients were used to examine associations between continuous variables according to their distribution. χ 2 was used to compare proportions. Multiple linear regression analyses were used to evaluate the influence of vitamin D and smoking status on echocardiographic variables. Statistical significance was considered when p < 0.05. SPSS version 12.0 was used (Statistical Package for Social Science, IBM).

Results

We evaluated 64 women, of whom nine were excluded due to diabetes (two subjects), chronic obstructive pulmonary disease (one subject), and BMI > 30 kg/m2 (six subjects). Thus, 55 women completed the study protocol.

The average age of the women smokers and ex-smokers was greater than 50 years old. The women in the three groups were classified as overweight. The history of smoking was similar between smokers and ex-smokers (Table 1).
Table 1

Clinical characteristics, smoking, and vitamin D status in the 55 women studied

Variables

Control (n = 19)

Smokers (n = 18)

Ex-smokers (n = 18)

p

Age (years)

44.4 ± 11.0a

52.8 ± 7.0b

51.7 ± 8.0b

0.011*

Smoking time (years)

0

31.3 ± 10.9

28.4 ± 9.0

0.896

BMI (kg/m2)

25.6 ± 3.7

26.0 ± 3.4

26.6 ± 2.7

0.636

FMI (kg/m2)

8.0 ± 2.6

8.6 ± 2.2

9.2 ± 1.5

0.262

FFMI (kg/m2)

16.9 ± 1.6

17.2 ± 2.1

17.4 ± 1.6

0.745

Vitamin D serum (ng/mL)

21.5 ± 6.4a

26.2 ± 10.4ab

30.2 ± 11.9b

0.033*

Vitamin D intake (μg/d)

4.2 ± 2.4

3.3 ± 2.7

3.15 ± 1.9

0.327

Freq sun expo

9.6 ± 4.5a

12.3 ± 4.6b

13.3 ± 3.9b

0.035*

Values followed by different letters (a, b) differ at 5 % by the multiple comparison test (Tukey’s test)

BMI body mass index, FMI fat mass index, FFMI fat-free mass index, Freq Sun Expo frequency of sun exposure questionnaire

*p < 0.05

There were no differences in body composition variables (FFMI and FMI) and vitamin D intake among the three groups. The sun exposure frequency questionnaire showed that the smoking subjects (smokers and ex-smokers) had a higher total score compared with the control subjects (Table 1).

Generally, most women studied showed sufficient vitamin D concentrations 65.5 %), and the proportions among the groups were not different. Furthermore, ex-smokers showed significantly higher vitamin D concentrations than the control group.

Echocardiographic morphometric variables are presented in Table 2. The smoker group showed a higher posterior wall thickness (PW), left ventricular mass (LVM), and left ventricular mass index (LVMI) compared with the control group. No differences were observed when comparing the other variables among the groups.
Table 2

Cardiac structure and diastolic and systolic functions of the 55 women studied, assessed by the echocardiography

Variables

Control (n = 19)

Smokers (n = 18)

Ex-smokers (n = 18)

p

LVD (mm)

37.0 ± 9.0

45.5 ± 4.41

44.5 ± 4.25

0.213

LVS (mm)

22.8 ± 1.78

26.8 ± 3.06

27.4 ± 3.75

0.493

PW (mm)

8.60 ± 0.54a

10.2 ± 2.13b

9.41 ± 1.53ab

0.023*

2PW/VED

0.49 ± 0.18

0.44 ± 0.66

0.42 ± 0.95

0.788

LVM (g)

115 ± 37.5a

208 ± 89.5b

173 ± 34.7ab

0.008*

LVMI

79.8 ± 21.8a

112 ± 36.4b

99.8 ± 18.6ab

0.002*

AD (mm)

27.2 ± 2.68

29.5 ± 2.34

29.4 ± 3.58

0.061

LAD (mm)

32.2 ± 2.04

35.7 ± 2.16

34.1 ± 3.83

0.175

LAD/AD

1.18 ± 0.96

1.21 ± 0.46

1.17 ± 0.20

0.844

Ejection fraction

0.77 (0.75–0.80)

0.77 (0.75–0.81)

0.77 (0.73–0.81)

0.985

Shortening fraction

0.33 ± 0.26

0.40 ± 0.61

0.38 ± 0.65

0.583

HR (bpm)

70.6 ± 4.09

72.0 ± 11.5

67.4 ± 8.88

0.391

CO (ml/min)

4562 ± 1405

4949 ± 1498

5002 ± 1333

0.550

E (cm/s)

84.4 ± 14.5a

71.8 ± 19.3ab

68.9 ± 19.1b

0.024*

A (cm/s)

74.0 ± 22.4

72.0 ± 18.4

59.9 ± 17.5

0.841

E/A

1.40 ± 0.57

1.01 ± 0.46

1.18 ± 0.53

0.196

Values followed by different letters (a, b) differ at 5 % by the multiple comparison test (Tukey’s test)

Abbreviations: LVD left ventricular diastolic diameter, LVS left ventricular systolic diameter, PW posterior wall thickness, 2PW/LVS relative wall thickness, LVM left ventricular mass, LVMI left ventricular mass index, AD aortic diameter, LAD left atrium diameter, LAD/AD left atrium diameter corrected by aorta, HR heart rate, CO cardiac output, E mitral E wave, A mitral A wave, E/A E wave/A wave ratio

*p < 0.05

Variables to evaluate systolic and diastolic function are also presented in Table 2. We observed that the ex-smoker group had shorter E waves compared with the control group. No differences were observed in other diastolic function variables among the groups. There were also no differences in systolic function variables among the groups.

Correlations between LVMI, PW, serum vitamin D concentrations, vitamin D intake, body composition, and time of smoking are shown in Table 3. We identified positive correlations between LVMI and smoking history, PW and serum vitamin D concentration, and BMI and time of smoking history. Smoking history was used in statistical models because of the higher correlation coefficient obtained in the univariate analysis (Table 3).
Table 3

Correlation analysis for the left ventricular mass index and posterior wall thickness

Variables

r

p

LVMI

  

 Vitamin D serum (ng/mL)

0.263

0.0526

 Vitamin D intake (μg/d)

−0.173

0.206

 BMI (kg/m2)

0.143

0.297

 FMI (kg/m2)

0.097

0.478

 FFMI (kg/m2)

0.127

0.356

 Smoking time (years)

0.437

0.0009*

PW (mm)

  

 Vitamin D serum (ng/mL)

0.314

0.0200*

 Vitamin D intake (μg/d)

−0.198

0.146

 BMI (kg/m2)

0.294

0.0293*

 FMI (kg/m2)

0.172

0.209

 FFMI (kg/m2)

0.261

0.0543

 Smoking time (years)

0.345

0.0102*

PW posterior wall thickness, LVMI left ventricular mass index, Freq Sun Expo frequency full sun exposure, PTH parathyroid hormone, BMI body mass index, FMI fat mass index, FFMI fat-free mass index

*p < 0.05

Multiple linear regressions revealed a positive association of smoking history, LVMI, and PW (Table 4). Moreover, serum vitamin D concentration was positively associated with PW. Only PW was associated with smoking history and serum vitamin D concentration, showing a deleterious effect of both variables on the heart.
Table 4

Multiple linear regression model for the left ventricular mass index and posterior wall thickness

Model

R 2

Adjusted (95 % confidence interval)

p

LVMI

   

 Smoking time (years)

0.229

1.002 (0.48–1.524)

<0.001*

LVMI

   

 Vitamin D serum (ng/mL)

0.0759

0.776 (−0.016–1.568)

0.056

LVMI

   

 Smoking time (years)

0.249

0.918 (0.378–1.458)

0.001*

 Vitamin D serum (ng/mL)

0.433 (−0.317–1.183)

0.253

PW (mm)

   

 Smoking time (years)

0.224

0.0416 (0.0148–0.0684)

0.003*

PW (mm)

   

 Vitamin D serum (ng/mL)

0.245

0.0534 (0.0156–0.0912)

0.007*

PW (mm)

   

 Smoking time (years)

0.310

0.0337 (0.0067–0.0607)

0.016*

 Vitamin D serum (ng/mL)

0.0408 (0.0034–0.0782)

0.034*

Adjusted for age and BMI

PW posterior wall thickness, LVMI left ventricular mass index

*p < 0.05

Discussion

The aim of this study was to evaluate the influence of serum vitamin D concentrations and smoking status in cardiac structure and function. Our results suggest that tobacco smoke and higher vitamin D levels induced cardiac remodeling.

Generally, the results showed that smokers and ex-smokers were older than subjects in the control group. The mean BMI classified the subjects as overweight, although the literature cited studied smokers who were underweight or are of normal weight [25]. Differences in fat mass were not observed among groups. The groups were also similar with respect to vitamin D intake; all of them ingested vitamin D below the recommended amount [23].

We observed significantly higher sun exposure indices in the smoker and ex-smoker groups compared with the control group. One possible explanation would be the largest solar exposition caused by smoking habit. In São Paulo state, an established law that prohibits smoking in collective public or private environments forced smokers to smoke in outdoors.

Circulating 25(OH) vitamin D3 concentration is the most suitable indicator of vitamin D status. This prohormone is stable and has a half-life of approximately 3 weeks [26]. However, the cutoff to define hypovitaminosis D is still not well established. Some authors consider levels higher than 30 ng/ml to define sufficiency [5], while others consider higher than 20 ng/mL an adequate cutoff level [23]. In this study, we used the most recent classification of the IOM [23]. This classification considered serum levels of 25(OH) vitamin D3 lower than 12 ng/mL as vitamin D deficiency and lower than 20 ng/mL as risk of vitamin D inadequacy.

Studies showed high prevalence of hypovitaminosis D in different populations worldwide, including Brazil. In certain Asian, European, and Latin American countries, hypovitaminosis D (<20 ng/mL) prevalence ranged from 20 to 83 % depending on the populations studied [27]. In Brazil, the rate of vitamin D deficiency ranged from 42 to 86 % [2830]. In the present study, 34.5 % of participants had 25(OH) vitamin D3 serum levels <20 ng/mL. The proportion of subjects at risk for vitamin D inadequacy was also not different among the groups. The majority of the subjects in the present study had an adequate vitamin D status.

Brot et al. [31] observed a higher frequency of vitamin D deficiency (20.9 %) in the smokers compared with the non-smokers group (13.7 %); however, we did not observe any difference. This finding and the similar serum 25(OH) vitamin D3 levels between control and smoking groups shows that the smoking habit does not influence vitamin D status. However, the ex-smoker group had higher serum vitamin D levels than the control group. This difference could be due to the higher sun exposure observed in ex-smokers.

The interest in the association of vitamin D and cardiovascular diseases came from animal models and epidemiological studies reporting increased cardiovascular events in subjects with vitamin D deficiency [4, 3234]. Several studies showed that vitamin D exerts a biphasic “dose-response” curve on cardiovascular physiopathology with deleterious consequences not only in the case of vitamin D deficiency but also when it is in excess [35, 36]. Both vitamin D deficiency [3741] and high vitamin D levels [4246] can be associated with structural and functional cardiovascular alterations. In the present study, we observed that serum 25(OH) vitamin D3 levels were associated with PW using the linear multiple regression model. An increase of 1 ng/mL in serum 25(OH) vitamin D3 caused a 0.05-mm increase in PW thickness. This finding suggests a deleterious consequence of high serum vitamin D levels on the heart.

Among the cellular and molecular changes that occur in the process of cardiac remodeling by vitamin D excess is oxidative stress. Chen and DeLuca [47] identified a gene (vitamin D upregulated (VDUP-1)) which is positively regulated by vitamin D promyelocytic cell line (HL-60). The VDUP-1 has been identified in several tissues including the heart [4851]. The protein encoded by VDUP-1 is also known as the thioredoxin-binding protein (TBP-2) or more days, as protein interactions with thioredoxin (TXNIP). It was given these names because, among other functions, it was identified as an endogenous negative regulator of protein thioredoxin (Trx), an important antioxidant protein in the heart [52]. This interaction blocks the binding of Trx with other factors, reducing their reducing activity [53, 54]. Another mechanism that might explain cardiac structural abnormalities could be the increased secretion of fibroblast growth factor 23 (FGF-23). Increased FGF-23 is associated with left ventricular hypertrophy in patients with chronic kidney disease [55, 56] and in patients with systolic heart failure [57]. In an experimental study in which FGF-23 was administered into mice atrium, the induction of cardiac hypertrophy was observed [58]. FGF-23 is one of the hormones that contributes to the regulation of serum phosphorus concentration [59], and it is also known that increasing the concentration of vitamin D increases intestinal absorption and serum phosphorous concentration [46, 60].

A main health disorder linked to smoking is cardiovascular disease [12, 13]. Smoking habits are reportedly associated with cardiac remodeling [12, 13, 61], which is associated with increased risk of heart failure and mortality. In the present study, we observed that the smoking group had higher values of PW thickness, left ventricle mass, and LVM index compared with the control group. In the multiple linear regression model in which LVMI was associated with time of smoking, each 1 year of smoking history increased the LVMI by 1.0 g. In another model, PW was associated with time of smoking, and each year in smoking history increased PW thickness by 0.04 mm. These higher LVM and PW values in smoking subjects were also observed in other studies [17, 62, 63].

The vitamin D-mediated protection effect against the smoking aggression [16] was not observed in the present study. In multiple linear regression models, we showed that vitamin D is another factor associated with the smoking effect in the heart.

What is new/novel about this research? Vitamin D and smoking are risk factors for cardiovascular disease. The present study suggests the deleterious effect of vitamin D to the heart. High serum vitamin D concentration is another factor associated with the action of smoking on cardiac variables.

Some limitations of this study have to be considered. Our study included a small number of women per group. Furthermore, the majority of women assessed were obese, which negatively correlates with vitamin D concentrations. The enrollment of only women limits the generalization of the study.

Conclusions

The smoking habit of adult women was associated with cardiac remodeling, and excess of vitamin D is associated with the action of smoking on cardiac variables. Thus, higher serum vitamin D values have a deleterious effect to the heart in this model.

Declarations

Acknowledgements

The authors would like to thank the following for helping to carry out this manuscript: Nicole Formaggi and Marina Bortolin, nutrition students; the employees of pulmonary function, blood collection, and X-rays; the nutritionist Ângela Valéria P. Barbin; the employees of the Department of Internal Medicine: Elizângela Silva, Bruno Fajiolli, Alexandre Loureiro, Renato Pereira, Laura Câmara, and Mario Dallaqua; the Higher Education Personnel Improvement Coordination (CAPES), by granting of the scholarship; and the Research Ethics Committee (Protocol CEP 4069-2011) by the work approval.

Authors’ contributions

MPF was responsible for the experimental design, preparation, coordination, and for conducting the study. She performed the statistical analysis and the manuscript redaction. SET was co-advisor, participating of the preparation and coordination of the research. She assisted in the statistical analysis and correction of the text. MGR realized the echocardiogram exams and supported in the interpretation of these results. CBM performed the spirometry tests used as an exclusion criterion, assisting in the interpretation of these results. KNMS conducted the exam requests, the interpretation of the biochemical tests, and the medical examination used as exclusion criteria. BFP supported the text revision. PSAG contributed with the elaboration of the study and text correction. MFM contributed with the results interpretation and text correction. LAMZ helped in the cardiac remodeling data interpretation. SJP was a co-advisor, participating of the preparation and coordination of the study. She also supported the interpretation of the results and text correction. IG contributed with the discussions about the research. SARP was an advisor, helping in the experimental design, preparation, and conducting the study. He also contributed to the statistical analysis and revision of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Internal Medicine, Botucatu Medical School
(2)
Department of Nursing, Botucatu Medical School

References

  1. James WP. 22 Marabou Symposium: the changing faces of vitamin D. Nutr Rev. 2008;66:S213–7.View ArticlePubMedGoogle Scholar
  2. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89.View ArticlePubMedGoogle Scholar
  3. Garcia VC, Martini LA. Vitamin D and cardiovascular disease. Nutrients. 2010;2:426–37.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Lichtenstein A, Ferreira-Junior M, Sales MM, Aguiar FB, Fonseca LA, Sumita NM, et al. Vitamin D: non-skeletal actions and rational use. Rev Assoc Med Bras. 2013;59:495–506.View ArticlePubMedGoogle Scholar
  5. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2014;810:500–25.PubMedGoogle Scholar
  6. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14:342–57.View ArticlePubMedGoogle Scholar
  7. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.View ArticlePubMedGoogle Scholar
  8. Dalbeni A, Scaturro G, Degan M, Minuz P, Delva P. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutr Metab Cardiovasc Dis. 2014;24:861–8.View ArticlePubMedGoogle Scholar
  9. Assalin HB, Rafacho BP, dos Santos PP, Ardisson LP, Roscani MG, Chiuso-Minicucci F, et al. Impact of the length of vitamin D deficiency on cardiac remodeling. Circ Heart Fail. 2013;6:809–16.View ArticlePubMedGoogle Scholar
  10. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol. 2008;51:559–64.View ArticlePubMedGoogle Scholar
  11. White WB. Smoking-related morbidity and mortality in the cardiovascular setting. Prev Cardiol. 2007;10:1–4.View ArticlePubMedGoogle Scholar
  12. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther. 2008;6:883–95.View ArticlePubMedGoogle Scholar
  13. Castardeli E, Paiva SA, Matsubara BB, Matsubara LS, Minicucci MF, Azevedo PS, et al. Chronic cigarette smoke exposure results in cardiac remodeling and impaired ventricular function in rats. Arq Bras Cardiol. 2005;84:320–4.View ArticlePubMedGoogle Scholar
  14. Azevedo PS, Minicucci MF, Matsubara BB, Matsubara LS, Duarte DR, Paiva SA, et al. Remodeling pattern and ventricular function in rats exposed to cigarette smoke. Arq Bras Cardiol. 2010;94:209–12. 224-208, 212-205.View ArticlePubMedGoogle Scholar
  15. Denipote F, Ardisson LP, Azevedo PS, Minicucci MF, Lima-Leopoldo AP, Chiuso-Minicucci F, et al. Influence of taurine on cardiac remodeling induced by tobacco smoke exposure. Cell Physiol Biochem. 2011;27:291–8.View ArticlePubMedGoogle Scholar
  16. Rafacho BP, Santos P, Assalin HB, Ardisson LP, Roscani MG, Polegato BF, et al. Role of vitamin D in the cardiac remodeling induced by tobacco smoke exposure. Int J Cardiol. 2012;155:472–3.View ArticlePubMedGoogle Scholar
  17. Gidding SS, Xie X, Liu K, Manolio T, Flack JM, Gardin JM. Cardiac function in smokers and nonsmokers: the CARDIA study. The Coronary Artery Risk Development in Young Adults Study. J Am Coll Cardiol. 1995;26:211–6.View ArticlePubMedGoogle Scholar
  18. Rosen BD, Saad MF, Shea S, Nasir K, Edvardsen T, Burke G, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2006;47:1150–8.View ArticlePubMedGoogle Scholar
  19. Hill TR, O’Brien MM, Lamberg-Allardt C, Jakobsen J, Kiely M, Flynn A, et al. Vitamin D status of 51-75-year-old Irish women: its determinants and impact on biochemical indices of bone turnover. Public Health Nutr. 2006;9:225–33.View ArticlePubMedGoogle Scholar
  20. Gill TK, Hill CL, Shanahan EM, Taylor AW, Appleton SL, Grant JF, et al. Vitamin D levels in an Australian population. BMC Public Health. 2014;14:1001.View ArticlePubMedPubMed CentralGoogle Scholar
  21. WHO. Obesity: preventing and managing the global epidemic. Report of a World Health Organization Consultation. Geneva: World Health Organization. 2000;894:256.
  22. Palacios C, Gil K, Perez CM, Joshipura K. Determinants of vitamin D status among overweight and obese Puerto Rican adults. Ann Nutr Metab. 2012;60:35–43.View ArticlePubMedPubMed CentralGoogle Scholar
  23. IOM Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, D.C.: The National Academies Press; 2011.Google Scholar
  24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.View ArticlePubMedGoogle Scholar
  25. Papini-Berto SJ, Carvalhaes MA, Moura EC. Tabagismo, estado nutricional e hábitos alimentares em população adulta de município paulista. Rev Ciênc Ext. 2011;7:57–70.Google Scholar
  26. Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5:819–29.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Arabi A, Rassi RE, Fuleihan GE-H. Hypovitaminosis D in developing countries—prevalence, risk factors and outcomes. Nat Rev Endocrinol. 2010;6:550–61.View ArticlePubMedGoogle Scholar
  28. Premaor MO, Paludo P, Manica D, Paludo AP, Rossatto ER, Scalco R, Furlanetto TW. Hypovitaminosis D and secondary hyperparathyroidism in resident physicians of a general hospital in southern Brazil. J Endocrinol Invest. 2008;31:991–5.View ArticlePubMedGoogle Scholar
  29. Silva BC, Camargos BM, Fujii JB, Dias EP, Soares MM. Prevalence of vitamin D deficiency and its correlation with PTH, biochemical bone turnover markers and bone mineral density, among patients from ambulatories. Arq Bras Endocrinol Metabol. 2008;52:482–8.View ArticlePubMedGoogle Scholar
  30. Unger MD, Cuppari L, Titan SM, Magalhaes MC, Sassaki AL, dos Reis LM, et al. Vitamin D status in a sunny country: where has the sun gone? Clin Nutr. 2010;29:784–8.View ArticlePubMedGoogle Scholar
  31. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53:920–6.View ArticlePubMedGoogle Scholar
  32. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.PubMedGoogle Scholar
  33. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, Marz W. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res. 2010;54:1103–13.PubMedGoogle Scholar
  34. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res. 2014;114:379–93.View ArticlePubMedGoogle Scholar
  35. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18:41–6.View ArticlePubMedGoogle Scholar
  36. Dror Y, Giveon SM, Hoshen M, Feldhamer I, Balicer RD, Feldman BS. Vitamin D levels for preventing acute coronary syndrome and mortality: evidence of a nonlinear association. J Clin Endocrinol Metab. 2013;98:2160–7.View ArticlePubMedGoogle Scholar
  37. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755–60.View ArticlePubMedGoogle Scholar
  38. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58:186–92.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Wasse H, Cardarelli F, De Staercke C, Hooper C, Veledar E, Guessous I. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol. 2011;12:24.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Giallauria F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P, et al. Arterial stiffness and vitamin D levels: the Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2012;97:3717–23.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Wong YY, Flicker L, Yeap BB, McCaul KA, Hankey GJ, Norman PE. Is hypovitaminosis D associated with abdominal aortic aneurysm, and is there a dose-response relationship? Eur J Vasc Endovasc Surg. 2013;45:657–64.View ArticlePubMedGoogle Scholar
  42. Hinek A, Botney MD, Mecham RP, Parks WC. Inhibition of tropoelastin expression by 1,25-dihydroxyvitamin D3. Connect Tissue Res. 1991;26:155–66.View ArticlePubMedGoogle Scholar
  43. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension. 1997;29:999–1006.View ArticlePubMedGoogle Scholar
  44. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98:1302–6.View ArticlePubMedGoogle Scholar
  45. Qin X, Corriere MA, Matrisian LM, Guzman RJ. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol. 2006;26:1510–6.View ArticlePubMedGoogle Scholar
  46. Santos PP, Rafacho BP, Goncalves Ade F, Jaldin RG, Nascimento TB, Silva MA, et al. Vitamin D induces increased systolic arterial pressure via vascular reactivity and mechanical properties. PLoS One. 2014;9:e98895.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Chen KS, DeLuca HF. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1994;1219(1):26–32.View ArticlePubMedGoogle Scholar
  48. Scheth SS, Castellani LW, Chari S, Wagg C, Thipphavong CK, Bodnar JS, et al. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res. 2005;46(1):123–34.View ArticleGoogle Scholar
  49. Wang Y, De Keulenaer GW, Lee RT. Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem. 2002;277(29):26496–500.View ArticlePubMedGoogle Scholar
  50. Oka S, Yoshihara E, Bizen-Abe A, Liu W, Watanabe M, Yodoi J, et al. Thioredoxin binding protein-2/thioredoxin-interacting protein is a critical regulator of insulin secretion and peroxisome proliferator-activated receptor function. Endocrinology. 2009;150(3):1225–34.View ArticlePubMedGoogle Scholar
  51. Filby CE, Hooper SB, Sozo F, Zahra VA, Flecknoe SJ, Wallace MJ. VDUP1: a potential mediator of expansion-induced lung growth and epithelial cell differentiation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2006;290(2):L250–8.View ArticlePubMedGoogle Scholar
  52. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999;274(31):21645–50.View ArticlePubMedGoogle Scholar
  53. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem. 2006;281(31):21884–91.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31(11):1287–312.View ArticlePubMedGoogle Scholar
  55. Negishi K, Kobayashi M, Ochiai I, Yamazaki Y, Hasegawa H, Yamashita T, et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ J. 2010;74(12):2734–40.View ArticlePubMedGoogle Scholar
  56. Unsal A, Kose Budak S, Koc Y, Basturk T, Sakaci T, Ahbap E, et al. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. Kidney Blood Press Res. 2012;36(1):55–64.View ArticlePubMedGoogle Scholar
  57. Gruson D, Lepoutre T, Ketelslegers JM, Cumps J, Ahn SA, Rousseau MF. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides. 2012;37(2):258–62.View ArticlePubMedGoogle Scholar
  58. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–5.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Zornoff LA, Matsubara LS, Matsubara BB, Okoshi MP, Okoshi K, Dal Pai-Silva M, et al. Beta-carotene supplementation attenuates cardiac remodeling induced by one-month tobacco-smoke exposure in rats. Toxicol Sci. 2006;90:259–66.View ArticlePubMedGoogle Scholar
  62. Vriz O, Nesbitt S, Krause L, Majahalme S, Lu H, Julius S. Smoking is associated with higher cardiovascular risk in young women than in men: the Tecumseh Blood Pressure Study. J Hypertens. 1997;15:127–34.View ArticlePubMedGoogle Scholar
  63. Gidding SS, Liu K, Colangelo LA, Cook NL, Goff DC, Glasser SP, et al. Longitudinal determinants of left ventricular mass and geometry: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Circ Cardiovasc Imaging. 2013;6:769–75.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2016

Advertisement